EudraCT Number Preparation Short title, Indication
2005
2005-000774-46 BM, autologous BOOST-2, myocardial regeneration
2005-000968-33 BM, autologous PROVASA, chronic limb ischemia [27]
2005-000969-19 BM, autologous RENERVATE, diabetic neuropathy
2005-003629-19 BM, autologous Myocardial regeneration
2006
2005-005709-50 BM, autologous CELLWAVE, Combined Extra corporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium
2005-004051-35 BM, autologous, CD133+ INSTEM, myocardial regeneration, combined with Trans Myocardial Laser Revascularisation (TMLR)
2006-000393-76 PB, allogeneic, CD3/CD19 depleted Hematological disorders in pediatric patients
2005-004028-38 BM, autologous, CD133+ Chronic cardiac ischemia
2007
2006-006404-11 PB, autologous, CD133+ PERFECT, Intramyocardial transplantation for Improvement of Post-Infarct Myocardial Regeneration in Addition to Surgery
2007-004874-14 BM, autologous REPAIR,Reinfusion of Enriched Progenitor cells And Infarct Remodeling in non-ST elevation AMl
2008
2007-007694-23 CB, autologous Umbilical cord blood to reverse DM type I in children
2006-001269-40 PB, autologous, CD34+ Severe lupus erythematodes
2007-006016-33 PB, allogeneic, CD3/CD19 depletion Reduced conditioning in adult leukemia patients
2008-004625-42 BM, autologous AMI; intramyocardial application
2007-003514-34 PB, allogeneic Comparing chemotherapy with stem cell transplantation in elderly with AML
2008-003658-13 PB, autologous EWING 2008; Ewing sarcoma, chemotherapy versus chemotherapy + HPC
2009
2008-008368-28 BM, autologous Ischemic cardiomyopathy, intramyocardial application
2007-004517-34 PB, allogeneic, CD3/CD19 depletion Relapsed or refractory AML (including children)
2010
2009-013856-61 PB, autologous multiple myeloma; combined with lenalidomid/dexamehtason
2010-019377-15 BM or PB, allogeneic AML; allogeneic HPC versus chemotherapy
2008-001669-27 PB, allogeneic Poor-risk CLL
2010-018467-42 PB, allogeneic MDS; 5-Azacytidine versus 5-Azacytidine + allogeneic HPC
AMI: Acute Myocardial Infarction; AML: Acute Myeloid Leukemia; CLL: Chronic Lymphatic Leukemia; DM: Diabetes mellitus; MDS: Myelo Dysplastic Syndrome.
Table 2: Clinical trials approved by the PEI in the years 2005 to 2010.